RCUS ARCUS BIOSCIENCES INC revenue, earnings and financials

For the quarter ended June 30, 2026, ARCUS BIOSCIENCES INC reported revenue of $41.0M (down 74.4% from a year earlier), net income of −$91.0M and diluted EPS of −$0.72; over the last four quarters revenue was $117M and net income −$460M; for the fiscal year ended December 2025 revenue was $247M, down 4.3% on the year before.

RCUS annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $247M, gross profit n/a, operating income −$386M, net income −$353M (margin -142.9%), EPS −$3.29
• Fiscal year ended Dec 2024: revenue $258M, gross profit n/a, operating income −$330M, net income −$283M (margin -109.7%), EPS −$3.14
• Fiscal year ended Dec 2023: revenue $117M, gross profit n/a, operating income −$340M, net income −$307M (margin -262.4%), EPS −$4.15
• Fiscal year ended Dec 2022: revenue $112M, gross profit n/a, operating income −$280M, net income −$267M (margin -238.4%), EPS −$3.71
• Fiscal year ended Dec 2021: revenue $383M, gross profit n/a, operating income $54.0M, net income $53.0M (margin 13.8%), EPS $0.71

RCUS quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $41.0M (down 74.4% year over year), net income −$91.0M, EPS −$0.72
• Quarter ended Mar 31, 2026: revenue $17.0M (down 39.3% year over year), net income −$128M, EPS −$1.02
• Quarter ended Dec 31, 2025 (from the annual report): revenue $33.0M (up 26.9% year over year), net income −$106M, EPS −$0.88
• Quarter ended Sep 30, 2025: revenue $26.0M (down 45.8% year over year), net income −$135M, EPS −$1.27
• Quarter ended Jun 30, 2025: revenue $160M (up 310.3% year over year), net income $0, EPS $0.00
• Quarter ended Mar 31, 2025: revenue $28.0M (down 80.7% year over year), net income −$112M, EPS −$1.14
• Quarter ended Dec 31, 2024 (from the annual report): revenue $26.0M (down 16.1% year over year), net income −$94.0M, EPS −$1.07
• Quarter ended Sep 30, 2024: revenue $48.0M (up 50.0% year over year), net income −$92.0M, EPS −$1.00
• Quarter ended Jun 30, 2024: revenue $39.0M (up 34.5% year over year), net income −$93.0M, EPS −$1.02
• Quarter ended Mar 31, 2024: revenue $145M (up 480.0% year over year), net income −$4.00M, EPS −$0.05
• Quarter ended Dec 31, 2023 (from the annual report): revenue $31.0M (down 8.8% year over year), net income −$81.0M, EPS −$1.08
• Quarter ended Sep 30, 2023: revenue $32.0M (down 3.0% year over year), net income −$71.0M, EPS −$0.94
• Quarter ended Jun 30, 2023: revenue $29.0M (up 7.4% year over year), net income −$75.0M, EPS −$1.04
• Quarter ended Mar 31, 2023: revenue $25.0M (up 38.9% year over year), net income −$80.0M, EPS −$1.09
• Quarter ended Dec 31, 2022 (from the annual report): revenue $34.0M (down 90.4% year over year), net income −$67.0M, EPS −$0.92
• Quarter ended Sep 30, 2022: revenue $33.0M (up 248.8% year over year), net income −$65.0M, EPS −$0.90
• Quarter ended Jun 30, 2022: revenue $27.0M (up 185.4% year over year), net income −$67.0M, EPS −$0.93
• Quarter ended Mar 31, 2022: revenue $18.0M (up 90.3% year over year), net income −$68.0M, EPS −$0.96
• Quarter ended Dec 31, 2021 (from the annual report): revenue $355M, net income $280M, EPS $3.99
• Quarter ended Sep 30, 2021: revenue $9.46M, net income −$78.0M, EPS −$1.11

RCUS cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$482M, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$170M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$306M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow $438M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$256M, share buybacks n/a

RCUS balance sheet

• Jun 30, 2026: cash $150M, total assets $924M, total liabilities n/a, shareholders' equity $464M
• Mar 31, 2026: cash $201M, total assets $997M, total liabilities n/a, shareholders' equity $524M
• Dec 31, 2025: cash $222M, total assets $1.14B, total liabilities n/a, shareholders' equity $631M
• Sep 30, 2025: cash $238M, total assets $974M, total liabilities n/a, shareholders' equity $436M
• Jun 30, 2025: cash $248M, total assets $1.08B, total liabilities n/a, shareholders' equity $549M
• Mar 31, 2025: cash $192M, total assets $1.16B, total liabilities n/a, shareholders' equity $531M
• Dec 31, 2024: cash $150M, total assets $1.15B, total liabilities n/a, shareholders' equity $485M
• Sep 30, 2024: cash $201M, total assets $1.25B, total liabilities n/a, shareholders' equity $565M

What is RCUS's revenue?

ARCUS BIOSCIENCES INC reported $117M of revenue over its last four quarters, through June 30, 2026.

Is RCUS profitable?

No. ARCUS BIOSCIENCES INC lost $460M over the last four quarters.

What is RCUS's EPS?

Diluted earnings per share over the last four quarters were −$3.89; −$0.72 in the latest quarter.

RCUS ownership and insider trades · All stocks